Neutralizing Antibody Titer | List of Frontiers open access articles

Original Research

Published on 16 Mar 2022

The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors

in Infectious Diseases – Surveillance, Prevention and Treatment

Marie Kroemer
Laura Boullerot
Mélanie Ramseyer
Laurie Spehner
Christophe Barisien
Eleonore Gravelin
Adeline Renaudin
Fabrice Cognasse
Pierre Gallian
Olivier Hermine

Frontiers in Public Health

doi 10.3389/fpubh.2022.816848

3,254 views
7 citations

Original Research

Published on 23 Jan 2024

A novel CpG ODN compound adjuvant enhances immune response to spike subunit vaccines of porcine epidemic diarrhea virus

in Vaccines and Molecular Therapeutics

Yating Wang
Shijia Liu
Boshuo Li
Xinyao Sun
Qi Pan
Yuxin Zheng
Jia Liu
Yongqiang Zhao
Jingyu Wang
Liming Liu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1336239

12,020 views
18 citations

Original Research

Published on 07 May 2020

Anti-HFRS Human IgG Produced in Transchromosomic Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models

in Virology

Casey C. Perley
Rebecca L. Brocato
Hua Wu
Christoph Bausch
Priya P. Karmali
Jerel B. Vega
Melanie V. Cohen
Brandon Somerville
Steven A. Kwilas
Lucia M. Principe

Frontiers in Microbiology

doi 10.3389/fmicb.2020.00832

7,452 views
28 citations

Original Research

Published on 27 Mar 2025

Chimeric receptor-binding domain vaccine design and sequential immunization enhanced broadly neutralizing antibody responses against COVID-19

in Vaccines and Molecular Therapeutics

Xiao Yang
Xin Tang
Ying Sun
Hualong Xi
Wei Peng
Lu Yan
Wenjing Teng
Yang Zang
Chunlai Jiang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1543212

2,947 views
3 citations

Original Research

Published on 28 Apr 2025

Preliminary evaluation of a novel serotype O foot-and-mouth disease mRNA vaccine

in Virology

Jingang Zhao
Peng Xiao
Aiguo Xin
Heran Zhu
Hao Wang
Jinlong Xiao
Hong Gao

Frontiers in Microbiology

doi 10.3389/fmicb.2025.1503191

4,900 views
1 citation

Original Research

Published on 16 Nov 2022

Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus

in Viral Immunology

Vladimir A. Gushchin
Darya A. Ogarkova
Inna V. Dolzhikova
Olga V. Zubkova
Igor V. Grigoriev
Andrei A. Pochtovyi
Anna A. Iliukhina
Tatiana A. Ozharovskaia
Nadezhda A. Kuznetsova
Daria D. Kustova

Frontiers in Immunology

doi 10.3389/fimmu.2022.1023164

5,223 views
13 citations

Original Research

Published on 24 Feb 2022

Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections

in Viral Immunology

Yukiya Kurahashi
Silvia Sutandhio
Koichi Furukawa
Lidya Handayani Tjan
Sachiyo Iwata
Shigeru Sano
Yoshiki Tohma
Hiroyuki Ohkita
Sachiko Nakamura
Mitsuhiro Nishimura

Frontiers in Immunology

doi 10.3389/fimmu.2022.773652

5,070 views
11 citations

Original Research

Published on 16 May 2023

A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients

in Clinical and Diagnostic Microbiology and Immunology

Takahiro Tomiyama
Rigel Suzuki
Noboru Harada
Tomokazu Tamura
Katsuya Toshida
Yukiko- Kosai-Fujimoto
Takahiro Tomino
Shohei Yoshiya
Yoshihiro Nagao
Kazuki Takeishi

Frontiers in Cellular and Infection Microbiology

doi 10.3389/fcimb.2023.1197349

3,214 views
9 citations

Original Research

Published on 21 Jan 2025

Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections

in Primary Immunodeficiencies

Dana Unninayar
Emilia L. Falcone
Hugo Chapdelaine
Donald C. Vinh
Karina A. Top
Beata Derfalvi
Thomas B. Issekutz
Hélène Decaluwe
Anne Pham-Huy
Julia Upton

Frontiers in Immunology

doi 10.3389/fimmu.2024.1501908

4,066 views
2 citations

Original Research

Published on 03 Apr 2024

Early B cell transcriptomic markers of measles-specific humoral immunity following a 3rd dose of MMR vaccine

in Systems Immunology

Iana H. Haralambieva
Jun Chen
Huy Quang Quach
Tamar Ratishvili
Nathaniel D. Warner
Inna G. Ovsyannikova
Gregory A. Poland
Richard B. Kennedy

Frontiers in Immunology

doi 10.3389/fimmu.2024.1358477

4,662 views
4 citations

Original Research

Published on 30 Jun 2022

Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center

in Vaccines and Molecular Therapeutics

Narayan Prasad
Shyam Bihari Bansal
Brijesh Yadav
Neha Manhas
Deependra Yadav
Sonam Gautam
Ravishankar Kushwaha
Ankita Singh
Dharmendra Bhadauria
Monika Yachha

Frontiers in Immunology

doi 10.3389/fimmu.2022.911738

3,336 views
12 citations

Original Research

Published on 30 Sep 2022

SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance

in Vaccines and Molecular Therapeutics

Monica Franzese
Luigi Coppola
Romina Silva
Stefano Angelo Santini
Luigi Cinquanta
Cosimo Ottomano
Marco Salvatore
Mariarosaria Incoronato

Frontiers in Immunology

doi 10.3389/fimmu.2022.947187

3,694 views
11 citations

Articles

The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors

A novel CpG ODN compound adjuvant enhances immune response to spike subunit vaccines of porcine epidemic diarrhea virus

Anti-HFRS Human IgG Produced in Transchromosomic Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models

Chimeric receptor-binding domain vaccine design and sequential immunization enhanced broadly neutralizing antibody responses against COVID-19

Preliminary evaluation of a novel serotype O foot-and-mouth disease mRNA vaccine

Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus

Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections

A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients

Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections

Early B cell transcriptomic markers of measles-specific humoral immunity following a 3rd dose of MMR vaccine

Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center

SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance